	Baseline	Month 6	р
BMI (kg/m <sup>2</sup> )	22.1±2.2	21.4±2.1	0.009
FSH (mIU/ml)	$6.1 \pm 1.8$	$6.4 \pm 3.3$	0.618
LH (mIU/ml)	11.4±6.9	$13.0 \pm 13.9$	0.636
Prolactin (ng/ml)	$15.4 \pm 6.8$	$14.6 \pm 7.4$	0.631
Testosterone (ng/dl)	82.9±17.5	$72.9 \pm 16.8$	0.036
$\Delta$ 4-A (ng/ml)	$3.1 \pm 0.8$	$2.9 \pm 0.8$	0.422
DHEA-S (ng/ml)	3320.8±800.4	3553.8±1152.3	0.325
FAI	$8.52 \pm 4.08$	$6.53 \pm 2.69$	0.030
17α-OHP (ng/ml)	$1.2 \pm 0.5$	$1.4 \pm 0.9$	0.196
SHBG (nmol/l)	$40.4 \pm 18.8$	43.4±15.3	0.262
Glucose (mg/dl)	98.8±16.6	$86.5 \pm 7.0$	< 0.001
Insulin (µIU/ml)	$18.7 \pm 31.7$	$10.5 \pm 9.7$	0.140
Glucose/insulin	$10.02 \pm 5.35$	$12.45 \pm 6.80$	0.147
HOMA-IR	$4.43 \pm 6.69$	$2.24 \pm 2.05$	0.070
QUICKI	$0.33 \pm 0.03$	$0.35 \pm 0.03$	0.009
PAI-1 (ng/ml)	39.9±12.3	$28.9 \pm 8.6$	< 0.001

**Table 1.** Changes in normal weight women with the polycystic ovary syndrome after 6 months of metformin treatment

BMI, body mass index; FSH, follicle stimulating hormone; LH, luteinizing hormone;  $\Delta$ 4-A,  $\Delta$ 4-androstenedione; DHEAS, dehydroepiandrosterone sulfate; FAI, free androgen index; 17 $\alpha$ -OHP, 17 $\alpha$ -hydroxyprogesterone; SHBG, sex hormone-binding globulin; HOMA-IR, homeostasis model assessment of insulin resistance; QUICKI, quantitative insulin sensitivity check index; PAI-1, plasminogen activator inhibitor 1.

Changes between baseline and month 6 were assessed with the paired samples t-test.